SecBot SecBot
PRESS-RELEASE ·Filed May 15, 2026

OTLK

Outlook Therapeutics, Inc.
BEARISH
Impact 6/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The FDA decision on ONS-5010 in May 2026 is the binary catalyst. Approval could drive significant upside; another CRL would likely be devastating given the $7.7M cash position and ongoing operating losses. The adjusted EPS miss and declining European sales add near-term pressure. Monitor the FDA decision closely, this is a high-risk, binary event stock.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.2290
T+0 close · May 15, 2026 · via day close
Latest settled
+288.21%
T+60 · $0.8890
Vs SPY
+282.63%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $0.2290entry
  2. T+1 · 6mo ago −0.44%α +0.23% · $0.2280
  3. T+5 · 6mo ago +74.67%α +73.06% · $0.4000
  4. T+20 · 5mo ago +585.59%α +584.01% · $1.57
  5. T+60 · 3mo ago +288.21%α +282.63% · $0.8890
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Outlook Therapeutics reported Q2 FY2026 results with GAAP net loss of $0.05/share (vs consensus $-0.12) and adjusted net loss of $0.16/share (vs consensus $-0.12). Revenue was $128K from initial LYTENAVA sales in Europe, but unit sales declined ~10% QoQ. The company completed a formal FDA dispute resolution meeting in April and expects a decision in May 2026, while cash stood at $7.7M (pre-April $4.2M offering).

Key Financial Metrics

EPS
−$0.16
est −$0.12 · -33.3%
Revenue
$128.0K
est $4.4M · -97.1%
Rating
miss

Key Facts

  • GAAP net loss per share: $(0.05) vs consensus $(0.12), beat on GAAP basis due to $9.3M in non-cash gains (warrant liability + promissory note fair value changes)
  • Adjusted (non-GAAP) net loss per share: $(0.16) vs consensus $(0.12), miss of 33% on the Street metric
  • Revenue: $128K from LYTENAVA European sales, down ~10% QoQ from Dec 2025 quarter
  • Cash and equivalents: $7.7M as of March 31, 2026 (excluding $4.2M net from April 2026 registered direct offering)
  • FDA formal dispute resolution meeting completed in April 2026; decision expected in May 2026
  • Convertible promissory note restructured with maturity extended to December 2026
  • March 2026 public offering raised ~$4.0M net; April 2026 registered direct offering raised $4.2M net

Financial Impact

Adjusted EPS miss of ~33% vs consensus; revenue of $128K with QoQ decline; cash runway extended by recent offerings but still limited

epsrevenuecashdilution

Risk Factors

  • FDA decision expected May 2026, negative outcome could render stock near-zero given limited cash
  • Cash burn continues with only $7.7M (pre-April offering), additional dilution likely
  • European LYTENAVA unit sales declined ~10% QoQ despite early launch momentum
  • High share count dilution: weighted average shares rose from 30.9M to 81.8M YoY

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
78% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3296119

Track record

37 reports on OTLK

Performance horizon

13 of 22 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 17 of 22 went positive at some point.

Filters
  1. Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
  2. Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
  3. Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
  4. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  5. Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  6. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
  7. Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
  8. Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  10. Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026